# AKASA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akasa

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.akasa.com
- Total disclosed funding: $85M
- Latest round: Series B (Mar 23, 2021)
- Investors on record: 3

## About

AKASA Inc., based in the US, specializes in advanced generative AI solutions for healthcare revenue cycle management, providing innovative tools that streamline workflows and enhance operational efficiency for healthcare providers.Founded in 2018, AKASA Inc. develops AI-driven solutions focused on healthcare revenue cycle management. The company was co-founded by Andy Atwal, Benjamin Beadle-Ryby, Malinka Walaliyadde, and Varun Ganapathi, with Malinka Walaliyadde currently serving as CEO. The firm has established its headquarters in San Francisco, US, and has completed 4 funding deals, with its most recent investment round occurring on June 18, 2024, where it raised USD 120 mn, bringing the total amount raised to USD 120 mn.AKASA provides advanced generative AI solutions specifically tailored for the healthcare revenue cycle. Their core product offerings integrate proprietary generative AI technology with deep revenue cycle management expertise to create impactful solutions that automate complex workflows and empower revenue cycle teams. Key functionalities include a GenAI assistant for prior authorization processes, coding recommendations that enhance comprehensiveness and accuracy, and automated claims status updates that alleviate administrative burdens. The company serves a diverse client base that includes over 650 hospitals and 6,500 outpatient facilities across all 50 states in the United States. By addressing the pressing financial pain points in revenue cycle management, AKASA enables health systems to improve their operational efficiency and focus on delivering better patient care.AKASA's revenue model is structured around B2B transactions with healthcare organizations, focusing on long-term partnerships to implement their GenAI solutions. Clients typically engage AKASA through subscription contracts that provide access to the company's suite of AI-powered revenue cycle management tools. These subscriptions include various tiers of service, allowing organizations to choose the level of support and features that best fit their operational needs. While specific pricing plans are not disclosed, the offerings are designed to deliver measurable improvements in efficiency and cost reduction, thereby enhancing overall revenue outcomes for healthcare providers. The firm continues to build its reputation as a leading provider of generative AI solutions in the healthcare sector.AKASA's strategy for future growth includes the design and launch of new AI products to enhance its offerings, with specific release dates to be announced. The company is also targeting expansion into new geographic regions, with plans to enter additional markets across North America by the end of 2025. The recent funding raised in June 2024, amounting to USD 120 mn, will be utilized to support these initiatives by enhancing product development and facilitating market entry.

## Funding rounds

- Series B, Mar 23, 2021, $60M — Andreessen Horowitz, Costanoa Ventures, Bond
- Series A, Jun 10, 2020, $20M — Andreessen Horowitz, Costanoa Ventures
- Seed, Dec 31, 2019, $5M — Andreessen Horowitz, Costanoa Ventures

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed, Series A, Series B
- Costanoa Ventures (https://capitalatlas.ai/funds/costanoa-ventures) — Seed, Series A, Series B
- Bond (https://capitalatlas.ai/funds/bond) — Series B